J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung cancer (NSCLC) patients who developed resistance and progressive diseases despite treatments.

J INTS BIO是一家开创性的生物制药公司，它公布了其新型第四代EGFR酪氨酸激酶抑制剂（TKI）JIN-A02的1/2期临床试验的有希望的中期结果，该试验针对EGFR突变的非小细胞肺癌（NSCLC）患者，尽管进行了治疗，但仍出现了耐药性和进行性疾病。

The data was presented at this year's edition of ENA (EORTC-NCI-AACR) Symposium, held in Barcelona, Spain, from October 23-25, 2024, drawing significant attention from the global oncology community.JIN-A02: A Next-Generation Therapeutic Targeting Resistance to 3rd-Generation EGFR-TKIsMutations in the epidermal growth factor receptor (EGFR) is a key driver in the pathogenesis of NSCLC, with 3rd Generation EGFR-TKIs like osimertinib serving as the cornerstone of treatment.

该数据于2024年10月23日至25日在西班牙巴塞罗那举行的今年版ENA（EORTC-NCI-AACR）研讨会上发布，引起了全球肿瘤学界的极大关注。JIN-A02：针对表皮生长因子受体（EGFR）中第三代EGFR TKIs突变的下一代治疗靶向抗性是NSCLC发病机制的关键驱动因素，第三代EGFR TKIs样osimertinib是治疗的基石。

Unfortunately, eventually resistance to this treatment will occur, leading to cancer relapse and disease progression. JIN-A02, developed by J INTS BIO, is the 4th-generation EGFR-TKI specifically designed to address this. By targeting both the original mutations and those acquired subsequently as a result of cancer treatments, it offers a therapeutic solution for these patients.The ongoing Phase 1/2 clinical trial evaluates JIN-A02 in patients with advanced or metastatic NSCLC who have developed resistance and disease progression after 3rd-generation EGFR-TKIs use.

不幸的是，最终会对这种治疗产生耐药性，导致癌症复发和疾病进展。由J INTS BIO开发的JIN-A02是专门为解决这个问题而设计的第四代EGFR-TKI。通过针对原始突变和随后由于癌症治疗而获得的突变，它为这些患者提供了治疗方案。正在进行的1/2期临床试验评估了使用第三代EGFR-TKIs后产生耐药性和疾病进展的晚期或转移性NSCLC患者的JIN-A02。

The study consist of 3 parts: dose escalation (Part A), dose exploration (Part B), and dose expansion (Part C). The data generated so far in Part A has been encouraging with a good safety profile and early efficacy signals, underscoring JIN-A02's position as a novel treatment for EGFR-TKI-resistant NSCLC.J INTS BIO said, 'New treatment are urgently needed for lung cancer patients whose disease has worsened or rel.

该研究由3部分组成：剂量递增（A部分），剂量探索（B部分）和剂量扩展（C部分）。到目前为止，A部分产生的数据令人鼓舞，具有良好的安全性和早期疗效信号，强调了JIN-A02作为EGFR TKI耐药NSCLC的新型治疗方法的地位。J INTS BIO说，“对于病情恶化或复发的肺癌患者，迫切需要新的治疗方法。